CN115996916B - 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 - Google Patents

用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法

Info

Publication number
CN115996916B
CN115996916B CN202180040296.8A CN202180040296A CN115996916B CN 115996916 B CN115996916 B CN 115996916B CN 202180040296 A CN202180040296 A CN 202180040296A CN 115996916 B CN115996916 B CN 115996916B
Authority
CN
China
Prior art keywords
compound
compounds
formula
och
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180040296.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN115996916A (zh
Inventor
D·基夫
郑国柱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kant Biomedical Co ltd
Original Assignee
Kant Biomedical Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kant Biomedical Co ltd filed Critical Kant Biomedical Co ltd
Priority to CN202511246796.3A priority Critical patent/CN121085765A/zh
Priority to CN202510664780.8A priority patent/CN120554211A/zh
Priority to CN202511246906.6A priority patent/CN121085756A/zh
Publication of CN115996916A publication Critical patent/CN115996916A/zh
Application granted granted Critical
Publication of CN115996916B publication Critical patent/CN115996916B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/28—Quinones containing groups having oxygen atoms singly bound to carbon atoms with monocyclic quinoid structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/695—Silicon compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C43/00—Ethers; Compounds having groups, groups or groups
    • C07C43/02—Ethers
    • C07C43/20—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring
    • C07C43/23—Ethers having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring containing hydroxy or O-metal groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
CN202180040296.8A 2020-04-03 2021-04-02 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法 Active CN115996916B (zh)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN202511246796.3A CN121085765A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202510664780.8A CN120554211A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246906.6A CN121085756A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063004639P 2020-04-03 2020-04-03
US63/004,639 2020-04-03
PCT/US2021/025558 WO2021202986A1 (en) 2020-04-03 2021-04-02 Compositions and methods for the prevention and/or treatment of mitochondrial disease, including friedreich's ataxia

Related Child Applications (3)

Application Number Title Priority Date Filing Date
CN202511246796.3A Division CN121085765A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246906.6A Division CN121085756A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202510664780.8A Division CN120554211A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法

Publications (2)

Publication Number Publication Date
CN115996916A CN115996916A (zh) 2023-04-21
CN115996916B true CN115996916B (zh) 2025-09-23

Family

ID=75728888

Family Applications (4)

Application Number Title Priority Date Filing Date
CN202180040296.8A Active CN115996916B (zh) 2020-04-03 2021-04-02 用于预防和/或治疗包括弗里德赖希共济失调的线粒体疾病的组合物和方法
CN202510664780.8A Pending CN120554211A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246796.3A Pending CN121085765A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246906.6A Pending CN121085756A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
CN202510664780.8A Pending CN120554211A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246796.3A Pending CN121085765A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法
CN202511246906.6A Pending CN121085756A (zh) 2020-04-03 2021-04-02 用于预防和/或治疗线粒体疾病的组合物和方法

Country Status (9)

Country Link
US (2) US12037350B2 (cg-RX-API-DMAC10.html)
EP (1) EP4126836A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023520462A (cg-RX-API-DMAC10.html)
KR (1) KR20230005855A (cg-RX-API-DMAC10.html)
CN (4) CN115996916B (cg-RX-API-DMAC10.html)
AU (1) AU2021246142A1 (cg-RX-API-DMAC10.html)
CA (1) CA3176909A1 (cg-RX-API-DMAC10.html)
IL (1) IL296985A (cg-RX-API-DMAC10.html)
WO (1) WO2021202986A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022291142A1 (en) 2021-06-10 2023-12-21 Stealth Biotherapeutics Inc. Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
US11541116B1 (en) 2022-01-07 2023-01-03 Kojin Therapeutics, Inc. Methods and compositions for inducing ferroptosis in vivo
WO2024263742A1 (en) * 2023-06-22 2024-12-26 Stealth Biotherapeutics Inc. Combination therapy for the treatment of friedreich's ataxia
AU2024300048A1 (en) * 2023-07-21 2026-01-22 Stealth Biotherapeutics Inc. Methods, compositions and uses related to the treatment and prevention of leigh's syndrome
AU2024377199A1 (en) 2023-11-09 2026-05-21 Stealth Biotherapeutics Inc. Cyclo-hexa-2,5-diene-1,4-diones for use in the treatment of cardiomyopathy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2018191732A1 (en) * 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
JP3507486B2 (ja) 1991-03-15 2004-03-15 アムジエン・インコーポレーテツド 顆粒球コロニー刺激因子の肺内投与
US5858784A (en) 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
US5674534A (en) 1992-06-11 1997-10-07 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5716644A (en) 1992-06-11 1998-02-10 Alkermes, Inc. Composition for sustained release of non-aggregated erythropoietin
US5451569A (en) 1994-04-19 1995-09-19 Hong Kong University Of Science And Technology R & D Corporation Limited Pulmonary drug delivery system
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
CA2272971C (en) 1998-10-29 2008-01-15 Institut National De La Sante Et De La Recherche Medicale (Inserm) Quinone derivatives for treating or preventing diseases associated with iron overload
US6245740B1 (en) 1998-12-23 2001-06-12 Amgen Inc. Polyol:oil suspensions for the sustained release of proteins
WO2005033092A1 (en) 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
EA035619B1 (ru) 2005-06-01 2020-07-16 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Композиции для использования в способе лечения митохондриальных нарушений
JP2009508867A (ja) 2005-09-15 2009-03-05 エジソン ファーマシューティカルズ， インコーポレイテッド ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
EP2332534B1 (en) 2006-02-22 2018-11-14 Bioelectron Technology Corporation Phenol and benzoquinone derivatives for use in the treatment of mitochondrial diseases and modulation of energy biomarkers
WO2009111576A2 (en) 2008-03-05 2009-09-11 Edison Pharmaceuticals, Inc. 2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
EP2303824B1 (en) 2008-06-25 2015-03-25 Edison Pharmaceuticals, Inc. 2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
EP2344142B1 (en) 2008-09-10 2024-06-26 PTC Therapeutics, Inc. Treatment of pervasive developmental disorders with redox-active therapeutics
WO2010051277A1 (en) 2008-10-28 2010-05-06 Edison Pharmaceuticals, Inc. Process for the production of alpha-tocotrienol and derivatives
EP2246048A1 (en) 2009-04-30 2010-11-03 Santhera Pharmaceuticals (Schweiz) AG Quinone derivative 2,3-dimethoxy-5-methyl-6-(10-hydroxydecyl)-1,4-benzoquinone for the treatment of primary progressive multiple sclerosis
NO2470168T3 (cg-RX-API-DMAC10.html) 2009-08-26 2018-06-30
US20130345312A1 (en) 2010-08-06 2013-12-26 Orion D. Jankowski Treatment of mitochondrial diseases with naphthoquinones
HRP20161407T1 (hr) 2010-08-16 2016-12-02 Santhera Pharmaceuticals (Schweiz) Ag Derivati benzokinona za liječenje mitohondrijskih bolesti oka
EP2606022A2 (en) 2010-08-16 2013-06-26 Santhera Pharmaceuticals (Schweiz) AG Novel benzoquinone derivatives and use thereof as modulators of mitochondrial function
WO2012068552A1 (en) 2010-11-19 2012-05-24 Edison Pharmaceuticals, Inc. Methods for improving blood glucose control
WO2012170773A1 (en) 2011-06-08 2012-12-13 Edison Pharmaceuticals, Inc. Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
CA2883879A1 (en) 2012-09-07 2014-03-13 Edison Pharmaceuticals, Inc. Quinone derivatives for use in the modulation of redox status of individuals
JP6367211B2 (ja) 2012-11-16 2018-08-01 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ リソソーム蓄積症の改善物質としてのトコフェロール誘導体およびトコフェリルキノン誘導体
JP2016515526A (ja) 2013-03-15 2016-05-30 エジソン ファーマシューティカルズ， インコーポレイテッド 酸化ストレス障害の処置のためのアルキル−ヘテロアリール置換されたキノン誘導体
WO2015183963A2 (en) 2014-05-28 2015-12-03 Stealth Peptides International, Inc. Therapeutic compositions including redox-active parabenzoquinones and uses thereof
EP3377179B1 (en) 2015-11-19 2021-04-07 Concert Pharmaceuticals Inc. Deuterated epi-743
EP3389646A1 (en) 2015-12-17 2018-10-24 BioElectron Technology Corporation Flouroalkyl, flouroalkoxy, phenoxy, heteroaryloxy, alkoxy, and amine 1,4-benzoquinone derivatives for treatment of oxidative stress disorders
CA3011293A1 (en) 2016-01-12 2017-07-20 Ptc Therapeutics, Inc. Tocopherol and tocotrienol quinone derivatives for increasing thiosulfate levels or decreasing hydrogen sulfide levels
JP7266304B2 (ja) 2017-04-21 2023-04-28 ユニヴァーシティー オブ タスマニア 治療化合物および方法
IL305687B2 (en) 2017-12-15 2024-12-01 Stealth Biotherapeutics Inc Mitochondria-targeting peptides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007100652A2 (en) * 2006-02-22 2007-09-07 Edison Pharmaceuticals, Inc. Side chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
WO2018191732A1 (en) * 2017-04-14 2018-10-18 Bioelectron Technology Corporation Methods and compositions for treatment of inflammation and oxidative stress

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
John E. Ezcurra, et al..Formation of reactive o-quinone methides from the reaction of trimethylsilyl(methyl)-substituted 1,4-benzoquinones with nucleophiles.Tetrahedron.2005,第61卷275-286. *
New, Simple and Selective Synthesis of Perfluoroalkylquinones by Perfluoroalkyl Radicals – Enthalpic and Polar Effects;Fabrizio Antonietti, et al.;Eur. J. Org. Chem.;20051231;4434-4440 *
Rapid Deoxyfluorination of Alcohols with 4-Chloro-N-tosylbenzene-1-Sulfonimidoyl Fluoride (SulfoxFluor) at Room Temperature;Jinbo Hu, et al.;Chemistry - A European Journal;201901176 *

Also Published As

Publication number Publication date
CN120554211A (zh) 2025-08-29
EP4126836A1 (en) 2023-02-08
CN121085765A (zh) 2025-12-09
CA3176909A1 (en) 2021-10-07
US20210317146A1 (en) 2021-10-14
AU2021246142A1 (en) 2022-10-20
IL296985A (en) 2022-12-01
CN121085756A (zh) 2025-12-09
US12037350B2 (en) 2024-07-16
US20240400588A1 (en) 2024-12-05
JP2023520462A (ja) 2023-05-17
CN115996916A (zh) 2023-04-21
WO2021202986A1 (en) 2021-10-07
KR20230005855A (ko) 2023-01-10

Similar Documents

Publication Publication Date Title
CN114746430B (zh) 治疗线粒体异常疾病的伐替苯醌的醌-、氢醌-和萘醌-类似物
CN120554211A (zh) 用于预防和/或治疗线粒体疾病的组合物和方法
TW202045469A (zh) 用於治療肺纖維化、肝纖維化、皮膚纖維化及心臟纖維化之經取代之芳族化合物
US20060189682A1 (en) Water soluble prodrugs of COX-2 inhibitors
US20240293339A1 (en) Compounds, compositions and methods for the prevention and/or treatment of various mitochondrial diseases or disorders, including friedreich's ataxia
CA2905606C (en) Guanidino benzoic acid esters useful in treating renal disorders
JP2023506496A (ja) 化合物及びα１－アンチトリプシン欠損症の治療のためのそれらの使用
WO2024239762A1 (zh) 磷酸二酯酶4抑制剂、其药物组合物及其应用
CN114349816B (zh) 一种基于氨肽酶n/cd13的小分子偶联分子及其制备方法和应用
HK40088188A (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
HK40088188B (en) Compositions and methods for preventing and/or treating mitochondrial diseases, including friedreich's ataxia
WO2012056976A1 (ja) アデニル酸シクラーゼの活性調節剤
CN113387909A (zh) 2,3-环氧丁二酰衍生物的医药用途
IT202400002560A1 (it) Inibitori della proteina rock per uso nel trattamento della fibrosi polmonare
CN118382435A (zh) 12/15-脂氧合酶抑制剂
CN116601166A (zh) 环Apelin受体激动剂
WO1995003053A1 (en) Oxophthalazines for treating cachexia

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40088188

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant